Emerging Therapies for Metabolic Bone Diseases

Metabolic bone diseases represent a substantial and growing global health concern, with conditions such as osteoporosis, osteoarthritis, Paget's disease, and rare genetic disorders like osteogenesis imperfecta, impairment of phosphate metabolism and others, severely impacting patient health and quality of life. Driven primarily by demographic aging and rising metabolic disorder prevalence, bone deterioration leads to persistent pain, heightened fracture risk, and reduced mobility. Traditional treatments like bisphosphonates and hormonal supplementation therapies have demonstrated limitations, including reduced efficacy over time, adverse reactions, and complications with long-term usage. Recently, advancements in regenerative medicine, targeted biological therapies, and novel pharmacological interventions have established transformative potential for addressing these treatment gaps. Notably, better understanding of molecular pathways underlying bone homeostasis, endocrine regulation, and potential therapeutic targets provide exciting opportunities, though much remains to be clarified regarding therapeutic precision, efficacy, and safety.


This Research Topic aims to examine state-of-the-art therapeutic advancements in human bone disease management, addressing significant clinical and translational challenges. It seeks to investigate pioneering therapeutic interventions capable of enhancing bone repair, thwarting disease progression, and significantly reducing adverse reactions or side effects. Specific aims include evaluating the efficacy of regenerative interventions such as gene and stem-cell therapies, analyzing biologic therapeutics targeting critical bone remodeling pathways, and scrutinizing novel small molecule candidates promoting bone mineralization. Furthermore, it emphasizes exploring precision medicine advances by evaluating patient-specific determinants, biomarkers, and individual genetic predispositions that impact treatment efficacy and outcomes. To achieve this, we welcome articles addressing, but not limited to, the following themes:


• Innovative pharmacological and biologic therapies – Novel drugs, combination treatments, repurposed medicines, monoclonal antibodies, and signaling modulators.

• Regenerative and cellular therapies – Stem cells, gene and cellular approaches, biomaterials, and tissue engineering.

• Precision and personalized medicine – Biomarkers, individualized risk assessment, and tailored treatments.

• Therapeutic targets in human bone disease – Key signaling pathways, sclerostin inhibition, parathyroid hormone analogs, and endocrine-metabolic regulation.

• Translational and clinical research – Clinical trials, real-world efficacy, and technological innovations.



We encourage submissions from basic scientists, clinicians, and translational researchers to foster interdisciplinary collaborations and accelerate meaningful discoveries, ultimately enhancing therapeutic strategies and patient outcomes in bone disease management.

Keywords: Bone, Disease, Management, Therapy, Medicine

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.